ArticleOncoTargets and therapy2018

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.

Liang Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.